Skip to main content

Table 1 Outcomes and follow-up periods

From: Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis

Studies Outcomes reported Follow-up periods DDC versus control group
CURRENT OASIS 7 [11] CV death, MI, or stroke (MACE); CV death, MI, stroke, total mortality, TIMI major bleeding, minor bleeding, fatal bleeding, intracranial bleeding 30 days DDC versus SDAPT
ACCEL AMI [12] Minor bleeding 30 days DDC versus SDAPT
OPTIMUS2007 [13] Bleeding complications 30 days DDC versus SDAPT
CREATIVE [14] MACE, all-cause death, cardiac death, MI, TVR, stroke, ST, major bleeding 18 months DDC versus SDAPT
Chen2017 [15] MACE, in-stent thrombosis, TVR, MI, cardiac death, bleeding events, mild bleeding, severe bleeding 12 months DDC versus SDAPT
Khatri2013 [16] Composite efficacy outcomes, any bleeding event 23 months DDC versus prasugrel
OPTIMUS3 [17] Major and minor TIMI defined bleeding, adverse drug events 7 days DDC versus prasugrel
PRINCIPLE TIMI 44 [18] TIMI major and minor bleeding, minor bleeding, hemorrhagic adverse events, MI 2 weeks DDC versus prasugrel
Tailor2014 [19] MACE, MI, ST, CV death, stroke 1 month and 571 days DDC versus prasugrel
Chen2017 [15] MACE, in-stent thrombosis, TVR, MI, cardiac death, bleeding events, mild bleeding, severe bleeding 12 months DDC versus ticagrelor
Wu2017 [20] MACE, minimal bleeding, minor bleeding 30 days DDC versus ticagrelor
ACCEL AMI [12] Minor bleeding 30 days DDC versus TAPT
ACCEL DM [21] Bleeding event 30 days DDC versus TAPT
CREATIVE [14] MACE, all-cause death, cardiac death, MI, TVR, stroke, ST, major bleeding 18 months DDC versus TAPT
Ha2013 [22] MACE 1 month DDC versus TAPT
HOST ASSURE [23] MACE, cardiac death, MI, stroke, ST, all-cause death, TLR, TVR, PLATO minor bleeding 30 days DDC versus TAPT
Jeong2009 [24] MACE, major and minor bleeding 30 days DDC versus TAPT
  1. Abbreviations: TAPT: triple antiplatelet therapy consisting of aspirin, clopidogrel and cilostazol, DDC: double dose clopidogrel, SDAPT: standard dual antiplatelet therapy, CV: cardiovascular, MI: myocardial infarction, ST: stent thrombosis, MACE: major adverse cardiac events, TIMI: thrombolysis in myocardial infarction, TVR: target vessel revascularization, TLR: target lesion revascularization
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us